Estonia Market Community

Optimi Health already makes and ships controlled psychedelic medicines to paying clinics, while most rivals are still waiting for approvals. The story hinges on whether a real, insured market can scale fast enough to fill its underused factory—before funding and rule changes become a problem.

31 Dec 2025 For shareholders of Novo Nordisk (NVO) , the past three years have been a masterclass in value creation. High margins, infinite demand, and a virtual monopoly in the obesity market drove the stock to record highs.

Zoetis makes medicines for pets and farm animals, but a sharp slowdown in its US pet business recently rattles investors and raises questions about how durable demand really is. The story hinges on whether its long track record of steady pricing and buybacks can keep the business resilient—or whether debt, product concentration, and copycat drugs start to bite.

Nuclear power is back in the spotlight as data centers and AI push demand for reliable electricity, but a lesser-known fuel shortage could slow down the next wave of new reactors. One U.S. supplier sits close to this choke point, while many reactor builders may be forced to wait until the fuel supply catches up.